Skip to content

Total debt at other companies

Eikon Therapeutics, Inc.
 logo
Eikon Therapeutics, Inc. EIKN
$254.83M
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$180.9M+69.8%
Replimune Group logo
Replimune GroupREPL
$79.21M+0.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$28.6M+10.1%
Erasca, Inc. logo
Erasca, Inc.ERAS
$45.95M-9.6%
Pfizer logo
PfizerPFE

Other financials

Income statement

See full
Revenue-
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation

See full
Market cap$184.2M+71.8%
Enterprise value-$7.49M-130%

Returns & leverage

See full
Return on equity-42.7%
Debt / equity0.0×
Current ratio13.8×+2.6×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $409K.

The official record: OnKure Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about OnKure Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OnKure Therapeutics, Inc.'s total debt?
OnKure Therapeutics, Inc. (OKUR) reported total debt of $409K in Q1 2026.
How has OnKure Therapeutics, Inc.'s total debt changed year-over-year?
OnKure Therapeutics, Inc.'s total debt decreased by 57.2% year-over-year, from $955K to $409K.
What is the long-term trend for OnKure Therapeutics, Inc.'s total debt?
Over 3 years (2022 to 2025), OnKure Therapeutics, Inc.'s total debt has grown at a -27.9% compound annual growth rate (CAGR), from $1.46M to $549K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.